|
Use of NCI Logo
The National Cancer Institute (NCI) logo
(Figure 1)
is a registered trademark that distinctly identifies the NCI.
Entities other than the NCI, the National Institutes of Health, or the U.S.
Department of Health and Human Services must receive formal approval prior to its
use on web sites or in written materials. Unauthorized use of the NCI logo may
constitute trademark infringement, as it may suggest NCI sponsorship or endorsement
of the policies, products, and services of other institutions.
At present, only the NCI–designated Comprehensive Cancer Center logo
(Figure 2)
is approved for use by cancer centers that have earned the comprehensive
designation through the peer review process.
Any NCI–designated Cancer Center currently using the NCI logo should remove
it from all websites and printed materials. The phrase, “National Cancer
Institute–designated Cancer Center” may be substituted in place of
the NCI logo graphic.
If you have further questions or concerns regarding the use of the NCI logo,
please contact:
Donna P. Bonner, MSPM
Publications Support Branch
National Cancer Institute
Telephone: (301) 496–4394
Email:bonnerd@mail.nih.gov
—posted 9/14/2007
|
|
Fiscal Year 07 Funding Memo
This memo is to advise you that, in accordance with NIH policy, Fiscal Year 07
non–competing (T5) P30 awards will be funded at approximately 97.1% of the Fiscal
Year 06 level. Administrative extensions at the request of the NCI (e.g., as part
of the recycling effort) will be funded at that level, as well.
Funding levels for Fiscal Year 07 competing (T1 and T2) and other types of
administrative extensions will be communicated individually to applicants, once
finalized.
We’d like to extend our thanks for your patience during this extended budget
process.
Please contact your program director if you have questions.
Linda K. Weiss, Ph.D.
Chief
Cancer Centers Branch
Office of Centers, Training, and Resources
National Cancer Institute
—posted 4/23/2007
Electronic Submission of Summaries 2, 3 and 4
Effective January 5, 2007, the Cancer Centers Branch is eliminating the requirement
for hard copy versions of Summaries 2–4 in Type 5 (non–competing) progress reports.
Electronic versions of these summaries must still be submitted to our office so that
they may be uploaded into the NCI official application file for your center.
Summaries 1 a, b, c, and d should continue to be submitted in both hard copy and
electronic format.
Please note that this change affects non–competing T5 applications only. Competing
Type 2 applications would still require both hard copy and electronic versions of all
summaries. If you have any questions about the summaries or their format, please call
(301) 496–8531. —posted 1/5/2007
New P30 Receipt Dates
Please note that, as per the
NIH Guide Notice, standing receipt dates for P30 CCSG applications will change effective
January 1, 2007. The new receipt dates will be January 25, May 25, and September 25. Inquiries
regarding this policy should be directed to the contact office noted in the announcement.
—posted 10/10/2006
Special Session on Assessment of Response to Therapy via Imaging Techniques
In 2005, the NCI Cancer Imaging Program and Cancer Centers Branch announced 8 Cancer Centers
as awardees of supplements for Imaging Response Assessment Teams (IRATs). A first meeting of
awardees, part of which will be open to other interested Center faculty, will be held in
March in Orlando in conjunction with the annual meeting of the Academy for Medical Imaging.
As a reminder, the concept of the IRATs grew out of discussions between the Association of
American Cancer Institutes and the NCI. IRAT supplemental awards are intended to facilitate
the development of a Cancer Center core that will advance the role of imaging in assessment
of response to therapy and increase the application of quantitative, anatomic, functional,
and molecular imaging endpoints in clinical therapeutic trials. Integration of IRAT team
members into the protocol planning process and increasing clinical collaborations between
imaging scientists and oncologic investigators is also a goal. When the three year supplemental
funding ends, each Center should have a committed shared resource.
The IRAT Network—the IRAT leaders and NCI leaders—and their collaborators
will convene for their first workshop, March 24–25, 2006, in Orlando. The workshop will
be an affiliate event of the Academy of Molecular Imaging's (AMI) annual conference at
the Gaylord Palms Resort and Convention Center, March 25–29. The IRAT workshop will
include a special session, Saturday, March 25, 12:00 to 2:00 p.m., that will be open
to the greater scientific and cancer center communities interested in and currently working
on issues related to the assessment of response to therapy via imaging techniques, and we
are encouraging interested scientists from all centers to attend.
Information about the AMI conference may be accessed through their website at
http://www.ami-imaging.org/conference2006/index.htm. For further information about
the workshop, please contact Maureen Pfeifer at Maureen@aaci–cancer.org or
(412) 647–6331.
—posted 3/1/2006
The University of New Mexico Cancer Research and Treatment
Center Receives NCI Designation
The University of New Mexico Cancer Research and Treatment Center (UNM CRTC) was
awarded the NCI designation in September of 2005, making it our 61st cancer center.
Dr. Cheryl Willman is the Director of the Center, which is the only NCI–designated
cancer center in the state of New Mexico. The Center was previously funded by a
five–year NCI P20 Cancer Center Planning Grant. The 91 members of the UNM CRTC are
clustered into 4 research programs that include Cancer epidemiology and Prevention,
Cancer Biology, Hematologic Malignancies, and Women’s Cancers. Research goals of
the Center are focused on New Mexico’s unique ethnic diversity and significant
economic and medical disparities, and the opportunities presented by their unique
partnerships. —posted 9/1/2005
|
